Sign in with Google
|
USD 51.40
Price
0.25
(0.49%)
Day Change
|
|
|---|
CORT, the overall quality is ok (Quality = 69) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Acceleration of net profit margin growth rate is below our criteria
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
54% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| Social Score | 4 |
| Magic Formula Rank by ROA |
1081
|
| Magic Formula Rank by ROE |
1081
|
| Magic Formula Rank by ROIC |
1007
|
| Price | 51.40 |
| PBV / Sector |
8.42 / 1.56
|
| Earning Per Share | 1.26 |
| PE / Sector |
40.60 / 16.11
|
| PEG or PE/Growth / Sector |
0.61 / 5.60
|
| Average 1M Daily Value |
51.54 M
|
| Average 1W Daily Value |
63.01 M
|
| Timing Factors |
|
28% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
68% |
| Return to Investors |
|
41% |
| Registration Details |
| Analyze Date | 2024-12-21 07:38:32 |
| Symbol | CORT |
| Name | CORCEPT THERAPEUTICS INCORPORATED |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 104.78 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 5,359.24 / 3,466.05 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
EXEL 
RPRX 
UTHR 
